Next-generation cell therapies: the emerging role of CAR-NK cells

Receptors in Detail


T cells with chimeric antigen receptors (CARs) have transformed cell therapy and shifted the treatment paradigm for many patients with recurrent or refractory B-cell malignancies. Despite this advancement, CAR-T cell treatment has limits in both autologous and allogeneic contexts, including practical, logistical, and toxicity concerns.


Given these issues, natural killer cells are gaining popularity as an alternate vehicle for CAR creation, thanks to their unique biological characteristics and well-established safety profile in the allogeneic environment.

Article Reference link: click here

Scientific article publishing date: 4/12/2020

Article identifier BSC22_413EN

Wir glauben an die Heilung von Krebs von innen heraus.

Finde mehr heraus!